SciSparc Ltd. (SPRC)

The immediate outlook is bearish despite a recent, sharp price rebound. While the stock surged from roughly $3 to nearly $5.40 over the last two weeks, this move is likely a technical bounce off multi-year lows rather than a reversal of the underlying trend. The asset is trading significantly below its 50-day and 200-day averages, indicating heavy selling pressure that has not yet been resolved. The statistical forecast model offers no help here, predicting a slight downward drift with very low confidence, which aligns with the weak technical structure. From a long-term perspective, the investment case is severely compromised. The company has endured four consecutive years of negative annual returns, with the cumulative loss over the past four years approaching 99.9%. This is not merely a cyclical downturn; it represents a structural collapse in shareholder value. Fundamentally, the business is deteriorating rapidly, evidenced by a 38.4% drop in revenue, negative operating margins of -17%, and negative free cash flow. The valuation metrics are distorted by the lack of earnings, showing a P/E of effectively zero and a massive P/S ratio of 152x, which suggests the market is pricing in a complete failure of the current business model. Although there is news of a Phase IIb trial for a Tourette's drug candidate, the historical data shows that previous pipeline developments have failed to arrest the stock's precipitous decline. The balance sheet is also fragile, with a current ratio below 1.0 and negative returns on equity and assets. There is absolutely no dividend support to consider; the company has paid no dividends in the last five years and is burning cash, making any expectation of income impossible.